文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

抗凝血酶Ⅲ用于脓毒症患者弥散性血管内凝血早期诊断:445例回顾性分析

[Antithrombin III for early diagnosis of DIC in sepsis patients: a retrospective analysis with 445 patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论脓毒症患者入ICU首日抗凝血酶Ⅲ水平可独立或联合凝血酶原时间诊断显性弥散性血管内凝血,抗凝血酶Ⅲ单独诊断界值48.5%。

该回顾性研究纳入2015年1至12月中国医科大学附属第一医院ICU收治的445例患者,其中脓毒症组138例、非脓毒症组307例。脓毒症患者入ICU首日抗凝血酶Ⅲ水平低于非脓毒症患者[(55.29±13.92)% vs.(76.54±12.31)%,P<0.01],显性弥散性血管内凝血组抗凝血酶Ⅲ水平低于非显性弥散性血管内凝血组和无弥散性血管内凝血组[(43.85±13.00)% vs.(56.95±13.03)%、(68.00±16.52)%,均P<0.05]。抗凝血酶Ⅲ联合凝血酶原时间诊断显性弥散性血管内凝血曲线下面积0.843,高于抗凝血酶Ⅲ单独0.763和凝血酶原时间单独0.834,敏感度90.0%、特异度73.7%;抗凝血酶Ⅲ单独诊断界值48.5%,敏感度78.0%、特异度70.0%。随着国际血栓与止血学会评分改善,抗凝血酶Ⅲ水平升高。

要点

  • 脓毒症患者入ICU首日抗凝血酶Ⅲ水平低于非脓毒症患者[(55.29±13.92)% vs.(76.54±12.31)%,P<0.01],提示抗凝血酶Ⅲ可辅助早期识别脓毒症相关凝血紊乱。
  • 显性弥散性血管内凝血(国际血栓与止血学会评分≥5分)患者首日抗凝血酶Ⅲ水平低于非显性弥散性血管内凝血和无弥散性血管内凝血组[(43.85±13.00)% vs.(56.95±13.03)%、(68.00±16.52)%,均P<0.05]。
  • 抗凝血酶Ⅲ联合凝血酶原时间诊断脓毒症相关显性弥散性血管内凝血曲线下面积0.843,敏感度90.0%、特异度73.7%,优于抗凝血酶Ⅲ单独(曲线下面积0.763)或凝血酶原时间单独(曲线下面积0.834)。
  • 抗凝血酶Ⅲ单独诊断显性弥散性血管内凝血的界值为48.5%,敏感度78.0%、特异度70.0%。
  • 脓毒症患者国际血栓与止血学会评分改善时抗凝血酶Ⅲ水平升高,早发型与晚发型弥散性血管内凝血患者抗凝血酶Ⅲ变化相似。

适用人群与场景

  • 2015年1至12月中国医科大学附属第一医院ICU收治的患者,按脓毒症诊断标准分为脓毒症组(138例)和非脓毒症组(307例)。
  • 脓毒症患者按入ICU首日国际血栓与止血学会评分分为显性弥散性血管内凝血组(评分≥5分,20例)、非显性弥散性血管内凝血组(评分1-4分,115例)和无弥散性血管内凝血组(评分=0分,3例)。

诊断标准与关键阈值

  • 显性弥散性血管内凝血诊断标准:入ICU首日国际血栓与止血学会评分≥5分;非显性弥散性血管内凝血为评分1-4分;无弥散性血管内凝血为评分0分。
  • 抗凝血酶Ⅲ单独诊断脓毒症相关显性弥散性血管内凝血的受试者工作特征曲线界值为48.5%,敏感度78.0%、特异度70.0%。
  • 抗凝血酶Ⅲ联合凝血酶原时间诊断显性弥散性血管内凝血的受试者工作特征曲线下面积0.843,敏感度90.0%、特异度73.7%。

研究设计与关键结果

  • 回顾性研究纳入445例ICU患者,脓毒症组138例、非脓毒症组307例;脓毒症患者入ICU首日抗凝血酶Ⅲ水平低于非脓毒症患者[(55.29±13.92)% vs.(76.54±12.31)%,P<0.01]。
  • 脓毒症患者中显性弥散性血管内凝血组首日抗凝血酶Ⅲ水平低于非显性弥散性血管内凝血组和无弥散性血管内凝血组[(43.85±13.00)% vs.(56.95±13.03)%、(68.00±16.52)%,均P<0.05]。
  • 脓毒症患者首日抗凝血酶Ⅲ水平与国际血栓与止血学会评分、凝血酶原时间呈负相关(r值分别为-0.467、-0.654,均P<0.01);显性弥散性血管内凝血患者首日抗凝血酶Ⅲ水平与凝血酶原时间呈负相关(r=-0.675,P=0.001)。
  • 受试者工作特征曲线显示,抗凝血酶Ⅲ联合凝血酶原时间诊断显性弥散性血管内凝血的曲线下面积高于抗凝血酶Ⅲ或凝血酶原时间单独(0.843 vs. 0.763、0.834),敏感度90.0%、特异度73.7%;抗凝血酶Ⅲ单独诊断界值48.5%,敏感度78.0%、特异度70.0%。
  • 脓毒症患者国际血栓与止血学会评分改善时抗凝血酶Ⅲ水平升高;早发型与晚发型弥散性血管内凝血患者抗凝血酶Ⅲ水平变化相似;弥散性血管内凝血改善时抗凝血酶Ⅲ水平升高。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对脓毒症患者,入ICU首日可检测抗凝血酶Ⅲ水平,辅助早期识别显性弥散性血管内凝血;抗凝血酶Ⅲ单独界值48.5%或联合凝血酶原时间可提高诊断敏感度至90.0%。
  • 动态监测抗凝血酶Ⅲ水平可能有助于反映脓毒症相关弥散性血管内凝血的改善,国际血栓与止血学会评分改善时抗凝血酶Ⅲ水平升高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigated the role of antithrombin III (AT-III) levels in the early diagnosis of disseminated intravascular coagulation (DIC) in patients with sepsis and the predictive effect of AT-III on the development of DIC.

METHODS: A retrospective study was conducted. Patients admitted to intensive care unit (ICU) of the First Affiliated Hospital of China Medical University from January to December in 2015 were enrolled. The patients were divided into sepsis group and non-sepsis group according to the diagnostic criteria of sepsis. In addition, sepsis patients were divided into 3 subgroups according to the international society on thrombosis and haemostasis (ISTH) scores on the first day: overt DIC (ISTH ≥ 5), non-overt DIC (ISTH 1-4) and none DIC group (ISTH = 0). Blood routine test, prothrombin time (PT), fibrinogen (Fib), D-dimer, fibrin degradation products (FDP), acute physiology and chronic health evaluation II (APACHE II) scores, sequential organ failure assessment (SOFA) scores and ISTH scores were recorded on the first ICU day. AT-III was recorded during 7 days. The differences were compared among these 3 groups. Correlations of AT-III with various parameters were calculated by using Pearson correlation analysis in sepsis group and overt DIC group. Receiver operating characteristic (ROC) curves for diagnosis of DIC with AT-III, AT-III+PT were drawn to evaluate the diagnostic efficiency. The AT-III levels of DIC patients were compared between early-onset DIC and late-onset DIC during their ICU stay. The change of AT-III levels with time and prognosis in patients with early-onset DIC was compared between groups.

RESULTS: Totally 445 patients were recruited, with 138 patients in sepsis group, and 307 in non-sepsis group. There were 20 patents diagnosed with overt DIC on the first ICU day, 115 patients non-overt DIC and 3 patients of none DIC. Twenty-five sepsis patients were diagnosed overt DIC during the ICU days. AT-III level in sepsis patients on the first ICU day were lower than that in non-sepsis patients [(55.29±13.92)% vs. (76.54±12.31)%, P < 0.01]. Patients with overt DIC had a lower AT-III level than non-overt DIC or none DIC patients [(43.85±13.00)% vs. (56.95±13.03)%, (68.00±16.52)%, both P < 0.05]. It was shown by Pearson correlation analysis that AT-III level of sepsis patients on the first ICU day was negatively correlated to ISTH score and PT (r value were -0.467, -0.654, both P < 0.01). AT-III level of overt DIC patient on the first ICU day was negatively correlated with PT (r = -0.675, P = 0.001). It was shown by ROC curve that area under ROC curve (AUC) of AT-III combined with PT for diagnosis overt DIC in sepsis patients was higher than that of AT-III or PT alone (0.843 vs. 0.763, 0.834), the sensitivity 90.0%, specificity 73.7%. The cut-off value for overt DIC diagnosis in sepsis patients of AT-III level alone was 48.5%, sensitivity was 78.0%, specificity was 70.0%. On the first ICU day, AT-III level was risen when ISTH score improved in patients with sepsis. There was similar change of AT-III level between patients with early-onset DIC and late-onset DIC. AT-III level increased with DIC improvement.

CONCLUSIONS: AT-III level can be used for diagnosing sepsis-associated overt DIC independently or with a combination of PT. When ISTH score improved, AT-III level was risen in patients with sepsis associated DIC.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Xu Y, Zhu R, Sun Y, et al. [Antithrombin III for early diagnosis of DIC in sepsis patients: a retrospective analysis with 445 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625259. doi:10.3760/cma.j.issn.2095-4352.2017.02.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。